FDA granted Fast Track designation to PDS0101 in combination with Merck’s anti-PD-1 therapy Keytruda (pembrolizumab) for the treatment of recurrent or metastatic HPV16-positive head and neck cancer.
Blue Note Therapeutics and OncoHealth have partnered to deliver oncology-specific mental health care.
C2i Genomics and Karkinos Healthcare have partnered to co-develop the minimal residual disease market in India.
Ultima Genomics is developing a high-throughput, low-cost sequencing platform that delivers $100 genome sequencing. Ultima has secured approximately $600 million in backing.
FDA approved Vidaza (azacitidine) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.
FDA granted marketing authorization to the Parsortix System for the harvesting of circulating cancer tumor cells in metastatic breast cancer.
FDA approved a combination of Tibsovo (ivosidenib) and Vidaza (azacitidine) for the treatment of patients with newly diagnosed IDH1-mutant acute myeloid leukemia who are 75 years or older or with comorbidities that prevent the use of induction chemotherapy.
An analysis conducted by Friends of Cancer Research showed that the FDA Breakthrough Therapy Designation criteria select drugs that lead to better outcomes for patients with lung cancer.
A committee of the European Medicines Agency recommended the approval for expanded use of Keytruda (pembrolizumab) as a standalone therapy for the adjuvant treatment of adults and adolescents aged 12 years and older with stage IIB or IIC melanoma who have undergone complete resection.
Case Western Reserve University signed an exclusive license agreement with Picture Health to develop AI technologies to help predict, diagnose, and treat lung cancer.
